

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Group Art Unit: 1636	:	
	:	
In re application of:	:	COMPOSITION COMPRISING A MOUSE
Sreekrishna et al.	:	HRT PROTEIN-HUMAN INTERACTING
	:	PARTNER PROTEIN COMPLEX
	:	
Application No.: 10/712,629	:	
	:	
Filing Date: November 13, 2003	:	

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT**  
**APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO**  
**ACID SEQUENCE DISCLOSURES**

Pittsburgh, Pennsylvania 15222  
May 30, 2008

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 22313 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Sequence Listing is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") mailed from the U.S. Patent and Trademark Office on May 1, 2008, having a one month period to respond.

**Remarks** begin on page 2 of this Notice.

### **REMARKS**

In response to the Notice, Applicants submit herewith a replacement Sequence Listing that complies with the requirements of 37 C.F.R. §§ 1.821 – 1.825. Applicants have amended the Sequence Listing to include the Genus/species for <213> and to include other relevant information for <223>. Specifically, <213> for SEQ ID NO: 17 has been amended to “Mus Musculus” and <223> for SEQ ID NO: 17 has been amended to recite “C-terminal portion of hairless protein of mouse (HRt) having amino acid residues 490 to 1182.” Further, <213> for SEQ ID NO: 18 has been amended to “Mus Musculus” and <223> for SEQ ID NO: 18 has been amended to recite “Nucleotide sequence of HRt corresponding to the amino acid residue of the C-terminal portion of HR protein.” In addition, <213> for SEQ ID NO: 19 and SEQ ID NO: 20 has been amended to “Artificial sequence.”

Support for these amendments is found in the originally submitted Sequence Listing. Support for the amendment to <213> and <223> for amended SEQ ID NO: 17 is found in the original descriptive portion of <213> of SEQ ID NO: 18, and support for the amendment to <213> and <223> for amended SEQ ID NO: 18 is found in the original descriptive portion of <213> of SEQ ID NO: 17. The descriptive portions in <213> of each sequence were inadvertently switched. It is apparent that the “C-terminal portion of hairless protein of mouse (HRt) having amino acid residues 490 to 1182” should be placed with SEQ. ID NO 17 and that the “Nucleotide sequence of HRt corresponding to the amino acid residue of the C-terminal portion of HRt protein,” should be placed with SEQ. ID NO 18 because the same protein is referenced, i.e., a mouse protein, as now stated in <223> of amended SEQ ID NO: 17. In the original Sequence Listing, SEQ ID NO: 17 includes an amino acid sequence, but is mistakenly identified as a nucleotide sequence. Likewise, in the original Sequence Listing, SEQ ID NO: 18 includes a nucleotide sequence, but is mistakenly identified as an amino acid sequence.


Support for the amendment to <213> of SEQ ID NO: 19 and SEQ ID NO: 20 is found in the original Sequence Listing, in which SEQ ID NO: 19 and SEQ ID NO: 20 are referred to as oligonucleotide primers. Applicants submit that the amendments to the Sequence Listing introduce no new matter and the Sequence Listing submitted herewith is intended to replace the Sequence Listing previously submitted on April 30, 2007. In addition, Applicants submit that

the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

If the undersigned can be of assistance to the Examiner in addressing any additional issues to advance the application to a condition of allowance, please contact the undersigned at the number set forth below.

Respectfully submitted,

Dated: May 30, 2008

  
Christine R. Ethridge  
Registration No. 30,557

KIRKPATRICK & LOCKHART PRESTON GATES ELLIS LLP  
Henry W. Oliver Building  
535 Smithfield Street  
Pittsburgh, Pennsylvania 15222  
Telephone: (412) 355-8619  
Facsimile: (412) 355-6501